Article Text

PDF

Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria
  1. Lorenzo Cavagna1,
  2. Santos Castañeda2,3,
  3. Carlo Sciré4,
  4. Miguel A Gonzalez-Gay5
  5. On Behalf of the AENEAS Collaborative Group Members
  1. 1Department of Rheumatology, University and IRCCS Foundation Policlinico S. Matteo, Pavia, Italy
  2. 2Department of Rheumatology, Hospital Universitario La Princesa, Madrid, Spain
  3. 3Department of Rheumatology, FJD, Madrid, Spain
  4. 4Dipartimento di Scienze Mediche, Universita degli Studi di Ferrara, Ferrara, Emilia-Romagna, Italy
  5. 5Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain
  1. Correspondence to Dr Lorenzo Cavagna, Departement of Rheumatology, University and IRCCS Foundation Policlinico S. Matteo, Pavia 27100, Italy; lorenzo.cavagna{at}unipv.it

Statistics from Altmetric.com

We read with great interest the extended report by Lilleker et al1 on the EuroMyositis registry. Our attention was particularly addressed to antisynthetase syndrome (ASSD) because in the last years we and all members of the AENEAS (American and European Network of Antisynthetase Syndrome) collaborative group strongly contributed2–7 to increase the knowledge on this peculiar disease.

We think that a comparison between our cohorts could be of interest and useful for clinicians, even if the lack of some data in the EuroMyositis paper does not allow us to perform statistical analysis. Both groups collected a very large number of patients (AENEAS collaborative group 813 cases, EuroMyositis 512 cases). The comparison of available …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.